阿西米尼布:下一代药物,用于慢性髓性白血病的第一线治疗
Chikashi Yoshida1, Tomoiku Takaku2
1Department of Hematology, NHO Mito Medical Center, Ibaraki, Japan.
Med (New York, N.Y.)
|August 10, 2024
概括
阿西米尼布是一种新型BCR::ABL1抑制剂,在新诊断的慢性骨髓性白血病患者中,其疗效和安全性优于标准的铁氨酸激酶抑制剂 (TKIs). 这一发现为慢性髓性白血病 (CML) 提供了一个有前途的新治疗方案.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性髓性白血病 (CML) 的标准治疗包括针对BCR::ABL1.1.的铁氨酸激酶抑制剂 (TKI).
- 阿西米尼布是一种具有独特机制的BCR::ABL1抑制剂,向ABL的myristoyl口袋.
研究的目的:
- 在新诊断的慢性阶段CML的患者中,与标准TKIs相比,评估阿司明尼布的疗效和安全性.
主要方法:
- 第三阶段随机对照试验 (ASC4FIRST试验).
- 在新诊断的慢性阶段CML患者中,Asciminib与标准TKI的比较.
主要成果:
- 与标准的TKIs相比,阿司明尼布显示出更高的疗效.
- 阿西米尼布在这个患者群体中表现出良好的安全性.
结论:
- 阿西米尼布代表了新诊断的慢性髓性白血病的优越和更安全的治疗选择.
- 用阿西米尼布准ABL的myristoyl口袋为CML提供了一个新的治疗策略.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
151
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
151


